CeraVx

CeraVx is a global biotechnology company dedicated to advancing healthcare through innovative drug delivery solutions. Specializing in the development and commercialization of a proprietary drug delivery platform based on ceramic micro-needle array patches (CeraMAPs™), CeraVx is positioned at the forefront of pharmaceutical manufacturing. The company's focus on prophylactic and therapeutic vaccines underscores its commitment to improving global health outcomes. CeraVx operates from its primary location at Leiden BioScience Park, BioPartner 4, Unit 4358, Robert Boyleweg 4, Leiden, 2333 CG, NL.

With a strong foundation in cutting-edge technology originating from the University of Twente's MESA+, Institute for Nanotechnology, CeraVx is dedicated to developing solutions for infectious diseases. The acquisition of proprietary micro-needle technology from MLT in 2024 further solidifies CeraVx's commitment to innovation and growth. The company’s strategic focus on dermal drug delivery and mRNA nano particles positions it as a key player in the evolving landscape of vaccine delivery.

CeraVx is committed to expanding its capabilities and contributing to advancements in the pharmaceutical industry. We invite the management team at CeraVx to create a customized and exclusive company showcase and product listing on our platform, enhancing their visibility and reach within the global market.